DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Malaysia
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
DPHARMA logo

Duopharma Biotech Berhad Stock Price

KLSE:DPHARMA Community·RM 1.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

DPHARMA Share Price Performance

RM 1.22
-0.16 (-11.59%)
​
RM 1.68
Fair Value
RM 1.22
-0.16 (-11.59%)
27.4% undervalued intrinsic discount
RM 1.68
Fair Value
Price RM 1.22
Haha94 RM 1.68
Wed, 6 Aug 25
Fair ValueRM 1.68
Share Pricen/a

DPHARMA Community Narratives

HA
Haha94's
Fair Value
·
Fair Value RM 1.68 27.4% undervalued intrinsic discount

Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition

1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
DPHARMA logo
Duopharma Biotech Berhad
27.4% undervalued intrinsic discount

Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition

View narrative
HA
Haha94
Updated 6 Aug 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

HA
DPHARMA logo

Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition

Fair Value: RM 1.68 27.4% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with solid track record and pays a dividend.

1 Risk
4 Rewards
View Full Analysis

Duopharma Biotech Berhad Key Details

RM 929.4m

Revenue

RM 545.8m

Cost of Revenue

RM 383.6m

Gross Profit

RM 281.4m

Other Expenses

RM 102.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.11
41.27%
11.00%
60.0%
View Full Analysis

About DPHARMA

Founded
1978
Employees
1957
CEO
Wan Bin Wan Abdul Majid
WebsiteView website
duopharmabiotech.com

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain products under the Donna brand name; skincare products under Dermoplex brand name; cosmeceuticals under the IRORO Nutreatment brand name; and functional food under the CHAMPS Nutribar and PROVITON STR Powerz brand names. The company also provides generic drugs for various therapeutic areas, such as cardiovascular, dermatology, hormonal, respiratory, sensory and nervous system, musculoskeletal, anti-infectives, and others; and specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables for the treatment of diabetes, cancer, cardiovascular, renal, and other diseases. In addition, it engages in the development of small molecules and biologic therapies for the treatment of Alzheimer’s disease; digital therapeutics; and stem cell therapies. Further, the company is involved in property management and services; and distribution of chemical products. It exports its products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. Duopharma Biotech Berhad was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.

Recent DPHARMA News & Updates

Recent updates

No updates

Duopharma Biotech Berhad Competitors

KOTRA logo

Kotra Industries Berhad

Symbol: KLSE:KOTRA
Market cap: RM 571.0m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide